On September 2, 2016, the PTAB terminated IPR2015-01624 and IPR2016-00460, both of which challenged U.S. Patent No. 6,331,415, one of Genentech’s Cabilly patents.  The Petitioners in those IPRs were Sanofi-Aventis and Genzyme, respectively.  The parties in each IPR had filed a joint request for termination following a confidential settlement agreement.  The termination documents and all other important biologic IPR documents are posted on our IPR tracker page.